Welcome to our dedicated page for Surrozen SEC filings (Ticker: SRZN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Surrozen, Inc. (SRZN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Surrozen uses these filings to report financial results, material events, executive appointments, collaboration changes, and other information relevant to its development of Wnt pathway–modulating therapeutics for severe eye diseases.
Current reports on Form 8-K are an important source of timely updates for SRZN. For example, Surrozen has filed 8-Ks to announce quarterly financial results, describe the appointment of a Chief Financial Officer and associated compensation arrangements, and disclose the termination of a collaboration agreement with TCGFB, Inc. for antibody discovery services. These filings often reference attached press releases that provide more detailed narrative on business performance and pipeline progress.
Investors can also use Surrozen’s periodic reports, such as its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, to review consolidated financial statements, research and development spending, and risk factor discussions. The company’s forward-looking statements in press releases explicitly point readers to these reports for a fuller description of risks related to its discovery, preclinical and potential clinical activities, funding needs, and collaboration structures.
On Stock Titan, Surrozen’s SEC filings are complemented by AI-powered summaries that highlight key points from lengthy documents, helping users quickly identify items such as revenue sources, operating expenses, non-cash fair value changes, and material agreements. Filings related to equity compensation and inducement grants under Nasdaq Listing Rule 5635(c)(4) can help users understand Surrozen’s use of stock options and warrants, while 8-K items on collaborations and licenses provide insight into related-party transactions and strategic partnerships, including the Boehringer Ingelheim agreement for SZN-413. Together, these filings offer a structured view of Surrozen’s financial condition, governance decisions, and development activities.
Surrozen, Inc. executive Li Yang received new equity awards consisting of stock options and restricted stock units. On February 17, 2026, Yang was granted options to purchase 100,950 shares of common stock at an exercise price of $0.00 per share and 100,950 restricted stock units.
The stock options vest over four years in 48 equal monthly installments starting February 1, 2026, conditioned on continued service. The RSUs vest in four equal annual installments beginning February 1, 2026, also subject to continued service. These awards represent direct ownership incentives rather than open-market share purchases.
Williams Charles O reported acquisition or exercise transactions in this Form 4 filing.
Surrozen, Inc. reported that its Chief Operating Officer, Charles O. Williams, received two new equity awards. On February 17, 2026, he was granted employee stock options covering 102,900 shares of common stock at a grant price of $0.00 per share. These option shares vest over four years in 48 equal monthly installments starting February 1, 2026, conditioned on continued service. He was also granted 102,900 restricted stock units, each representing one share of common stock, which vest in four equal annual installments beginning February 1, 2026, also subject to continued service.
Surrozen, Inc. reported that Chief Executive Officer Craig C. Parker received new equity awards. On February 17, 2026, he was granted an employee stock option covering 242,200 shares of common stock at an exercise price of
The option vests over four years in 48 equal monthly installments starting from
Braidwell and affiliates disclosed a significant position in Surrozen, Inc. common stock. As of December 31, 2025, Braidwell LP, Braidwell Management LLC, Alexander T. Karnal, and Brian J. Kreiter may be deemed beneficial owners of 470,000 shares, representing about 5.5% of Surrozen’s outstanding common stock.
All 470,000 shares are directly owned by Braidwell Partners Master Fund LP, with each reporting person sharing voting and dispositive power and no sole authority. The stake is reported as being held in the ordinary course of business and not for the purpose of changing or influencing control of Surrozen.
Surrozen, Inc. received an updated ownership report showing that RA Capital Management, its affiliated fund, and principals Peter Kolchinsky and Rajeev Shah collectively report beneficial ownership of 871,731 shares of common stock, representing 9.2% of the class as of December 31, 2025.
The position includes Series A warrants for up to 322,580 shares, Series B warrants for up to 350,876 shares, and Series E warrants for up to 198,275 shares of common stock. The filing states the securities are not held for the purpose of changing or influencing control of Surrozen.
StemPoint Capital and related parties reported a significant ownership stake in Surrozen, Inc. The Schedule 13G/A shows StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross collectively beneficially owning 619,766 shares of Surrozen common stock, including 329,658 shares issuable upon exercise of warrants.
This represents 7.0% of Surrozen’s common stock, calculated using 8,571,421 shares outstanding as of November 5, 2025, plus specified Series A, B, and E warrants subject to a 9.9% beneficial ownership limitation. The filers state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Surrozen.
Stonepine Capital Management, Stonepine Capital, Stonepine GP and Jon M. Plexico filed an amended Schedule 13G reporting beneficial ownership of 316,289 shares of Surrozen, Inc. common stock, representing 3.6% of the class as of the reported date.
The stake consists of 113,631 shares of common stock plus 202,658 shares issuable upon exercise of Series A, Series B and Series E warrants, all subject to a 9.9% beneficial ownership limitation. The percentage is based on 8,571,421 shares outstanding as of November 5, 2025, and the filers certify the holdings are not for the purpose of changing or influencing control.
TCG Crossover investment entities increased their indirect stake in Surrozen, Inc. common stock through open-market purchases. On February 11, 2026, TCG Crossover Fund II, L.P. and TCG Crossover Fund III, L.P. each bought 8,882 and 8,881 shares at $23.575 per share, respectively. On February 12, 2026, they bought additional blocks of 547 and 546 shares at $23.8625 per share. After these transactions, one fund reported beneficial ownership of 651,114 shares and the other 651,112 shares, all held indirectly through the TCG Crossover fund structure.
Surrozen, Inc. (SRZN) received an amended Schedule 13G from several Millennium-related investment entities reporting significant passive ownership of its common stock as of 12/31/2025. Integrated Core Strategies (US) LLC reports beneficial ownership of 718,724 shares, representing 8.4% of the outstanding common stock.
Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each report beneficial ownership of 726,193 shares, or 8.5% of the class, with shared voting and dispositive power and no sole voting or dispositive power. The filing states these securities are held through entities over which Millennium Management LLC and related managers exercise voting control and investment discretion.
The reporting persons certify the securities were not acquired and are not held for the purpose of changing or influencing control of Surrozen, and the filing is made under the passive ownership framework of Schedule 13G.
TCG Crossover investment entities reported open-market purchases of Surrozen, Inc. (SRZN) common stock. On January 30, 2026, TCG Crossover Fund II, L.P. bought 2,136 shares at
On February 2, 2026, Fund II purchased 366 shares at